Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates
Abstract Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-024-03004-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147436412665856 |
|---|---|
| author | Linh Nguyen Tiep Tien Nguyen Ju-Yeon Kim Jee-Heon Jeong |
| author_facet | Linh Nguyen Tiep Tien Nguyen Ju-Yeon Kim Jee-Heon Jeong |
| author_sort | Linh Nguyen |
| collection | DOAJ |
| description | Abstract Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resistance, prolonged treatment duration, and low efficacy in clearing viral antigens. To address these challenges in current HBV treatment, numerous approaches have been developed with remarkable success. Among these strategies, small-interfering RNA (siRNA) stands out as one of the most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, and unable to cross the cell membrane due to their large, anionic structure. Therefore, effective delivery systems are required to protect siRNAs and maintain their functionality. In this review, we have discussed the promises of siRNA therapy in treating HBV, milestones in their delivery systems, and products that have entered clinical trials. Finally, we have outlined the future perspectives of siRNA-based therapy for HBV treatment. Graphical Abstract |
| format | Article |
| id | doaj-art-b47f85c7e95d43b7a3f0c852394767c7 |
| institution | Kabale University |
| issn | 1477-3155 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj-art-b47f85c7e95d43b7a3f0c852394767c72024-12-01T12:43:13ZengBMCJournal of Nanobiotechnology1477-31552024-11-0122111910.1186/s12951-024-03004-3Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updatesLinh Nguyen0Tiep Tien Nguyen1Ju-Yeon Kim2Jee-Heon Jeong3Department of Precision Medicine, School of Medicine, Sungkyunkwan UniversityDepartment of Precision Medicine, School of Medicine, Sungkyunkwan UniversityDepartment of Precision Medicine, School of Medicine, Sungkyunkwan UniversityDepartment of Precision Medicine, School of Medicine, Sungkyunkwan UniversityAbstract Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resistance, prolonged treatment duration, and low efficacy in clearing viral antigens. To address these challenges in current HBV treatment, numerous approaches have been developed with remarkable success. Among these strategies, small-interfering RNA (siRNA) stands out as one of the most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, and unable to cross the cell membrane due to their large, anionic structure. Therefore, effective delivery systems are required to protect siRNAs and maintain their functionality. In this review, we have discussed the promises of siRNA therapy in treating HBV, milestones in their delivery systems, and products that have entered clinical trials. Finally, we have outlined the future perspectives of siRNA-based therapy for HBV treatment. Graphical Abstracthttps://doi.org/10.1186/s12951-024-03004-3siRNAHepatitis BDelivery systemConjugationLipid |
| spellingShingle | Linh Nguyen Tiep Tien Nguyen Ju-Yeon Kim Jee-Heon Jeong Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates Journal of Nanobiotechnology siRNA Hepatitis B Delivery system Conjugation Lipid |
| title | Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates |
| title_full | Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates |
| title_fullStr | Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates |
| title_full_unstemmed | Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates |
| title_short | Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates |
| title_sort | advanced sirna delivery in combating hepatitis b virus mechanistic insights and recent updates |
| topic | siRNA Hepatitis B Delivery system Conjugation Lipid |
| url | https://doi.org/10.1186/s12951-024-03004-3 |
| work_keys_str_mv | AT linhnguyen advancedsirnadeliveryincombatinghepatitisbvirusmechanisticinsightsandrecentupdates AT tieptiennguyen advancedsirnadeliveryincombatinghepatitisbvirusmechanisticinsightsandrecentupdates AT juyeonkim advancedsirnadeliveryincombatinghepatitisbvirusmechanisticinsightsandrecentupdates AT jeeheonjeong advancedsirnadeliveryincombatinghepatitisbvirusmechanisticinsightsandrecentupdates |